Embryologic outcomes among patients using a microfluidics chip compared to density gradient centrifugation to process sperm: a paired analysis.


Journal

Journal of assisted reproduction and genetics
ISSN: 1573-7330
Titre abrégé: J Assist Reprod Genet
Pays: Netherlands
ID NLM: 9206495

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 21 01 2022
accepted: 21 04 2022
pubmed: 27 5 2022
medline: 13 8 2022
entrez: 26 5 2022
Statut: ppublish

Résumé

To evaluate embryologic outcomes among paired IVF cycles in which a microfluidics chip was utilized compared to density gradient centrifugation for sperm processing. This was a retrospective cohort study of 88 paired IVF cycles from patients aged 18-44 years at a university-affiliated IVF center. Fresh cycles from patients undergoing ICSI with sperm processed by a microfluidics chamber (microfluidics cycles) were compared to the same patients' previous ICSI cycles in which sperm was processed via density gradient centrifugation (control cycles). The primary outcome was the high-quality blastulation rate. High-quality blastulation rate per oocyte retrieved was significantly higher in the microfluidics group compared to the control group (21.1% versus 14.5%, p < 0.01) as was the blastulation rate per 2PN (42.7% versus 30.8%, p < 0.01). Fertilization rates were significantly higher in the microfluidics group. The euploidy rate per oocyte retrieved was significantly higher in the microfluidics group compared with the control group (8.5% versus 4.3%, p = 0.04), while the euploidy rate per embryo biopsied was comparable (32.6% versus 21.8%, p = 0.09). In patients with male factor infertility, the high-quality blastulation rate was similar between the control and microfluidics cycles. There was a significantly higher blastulation rate among microfluidics cycles in patients without a diagnosis of male factor infertility (p < 0.01). In this study, several embryologic outcomes, including fertilization rate, high-quality blastulation rate, and euploidy rate, were significantly higher in the microfluidics group compared to the control group. Microfluidics sperm processing may be a way to improve embryologic outcomes.

Identifiants

pubmed: 35619041
doi: 10.1007/s10815-022-02504-1
pii: 10.1007/s10815-022-02504-1
pmc: PMC9365916
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1523-1529

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Fertil Steril. 2021 Sep;116(3):757-765
pubmed: 34045067
Hum Fertil (Camb). 2013 Sep;16(3):175-93
pubmed: 23862664
Syst Biol Reprod Med. 2021 Apr;67(2):137-143
pubmed: 33451252
J Assist Reprod Genet. 2019 Oct;36(10):2057-2066
pubmed: 31418108
J Assist Reprod Genet. 2019 Mar;36(3):403-409
pubmed: 30542782
J Reprod Med. 2011 Jan-Feb;56(1-2):12-6
pubmed: 21366121
Hum Reprod. 2018 Aug 1;33(8):1388-1393
pubmed: 30007319
Fertil Steril. 2011 Jun 30;95(8):2531-3
pubmed: 21324455
J Assist Reprod Genet. 2018 Nov;35(11):1953-1968
pubmed: 30206748
Biotechnol Adv. 2020 May - Jun;40:107498
pubmed: 31836499
Zygote. 2022 Apr;30(2):200-205
pubmed: 34313213
Theriogenology. 2016 Apr 15;85(7):1289-96
pubmed: 26777560
Biol Reprod. 2019 Dec 24;101(6):1076-1082
pubmed: 30801632
Hum Reprod Update. 2010 May-Jun;16(3):231-45
pubmed: 19934213
Curr Opin Obstet Gynecol. 1999 Jun;11(3):307-11
pubmed: 10369209
J Reprod Infertil. 2019 Jul-Sep;20(3):121-126
pubmed: 31423414
Mol Hum Reprod. 2017 Apr 1;23(4):257-268
pubmed: 28130394
Front Cell Dev Biol. 2019 Nov 29;7:298
pubmed: 31850340
Andrologia. 2019 Nov;51(10):e13403
pubmed: 31434165
Mutat Res Rev Mutat Res. 2020 Jul - Sep;785:108320
pubmed: 32800274
Reprod Biol Endocrinol. 2003 Nov 14;1:108
pubmed: 14617368
Fertil Steril. 2019 Jul;112(1):54-60.e3
pubmed: 31056315
Reprod Biomed Online. 2019 Sep;39(3):372-382
pubmed: 31109895
Reprod Biomed Online. 2006 May;12(5):608-15
pubmed: 16790106
Reprod Sci. 2022 Jun;29(6):1801-1808
pubmed: 34731459

Auteurs

Prachi Godiwala (P)

Center for Advanced Reproductive Services, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, CT, USA.

Emilse Almanza (E)

University of Connecticut School of Medicine, Farmington, CT, USA.

Jane Kwieraga (J)

Center for Advanced Reproductive Services, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, CT, USA.

Reeva Makhijani (R)

Center for Advanced Reproductive Services, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, CT, USA.

Daniel Grow (D)

Center for Advanced Reproductive Services, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, CT, USA.

John Nulsen (J)

Center for Advanced Reproductive Services, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, CT, USA.

Claudio Benadiva (C)

Center for Advanced Reproductive Services, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, CT, USA.

Alison Bartolucci (A)

Center for Advanced Reproductive Services, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, CT, USA.

Lawrence Engmann (L)

Center for Advanced Reproductive Services, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, CT, USA. lengmann@uchc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH